Travere Therapeutics Reports First Quarter 2022 Financial Results
05 mai 2022 16h01 HE
|
Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
15 déc. 2021 07h00 HE
|
Travere Therapeutics, Inc.
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
Travere Therapeutics Reports Second Quarter 2021 Financial Results
29 juil. 2021 16h01 HE
|
Travere Therapeutics, Inc.
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track...
Travere Therapeutics to Present at Upcoming Investor Conferences
22 févr. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
11 févr. 2021 22h03 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a...